Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | SMAD3 | P84022 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31023772 | 0.95 | P4HB (0.47) | P4HBCYP2D6CYP19A1MEN1KMT2A | |
| SCHEMBL31023777 | 0.83 | USP2 (0.51) | P4HBCYP2D6CYP19A1MEN1KMT2A | |
| SCHEMBL31023828 | 0.81 | CHRNB2 (0.38) | P4HBCYP2D6CYP19A1MEN1KMT2A | |
| SCHEMBL31023829 | 0.81 | CHRNB2 (0.38) | P4HBCYP2D6CYP19A1MEN1KMT2A | |
| SCHEMBL31023749 | 0.80 | P4HB (0.39) | P4HBCYP2D6CYP19A1MEN1KMT2A | |
| SCHEMBL31023682 | 0.79 | USP2 (0.37) | P4HBCYP2D6MEN1KMT2ASMAD3 | |
| SCHEMBL31023902 | 0.79 | USP2 (0.50) | P4HBCYP2D6SMAD3ALDH1A1 | |
| SCHEMBL17276381 | 0.77 | CYP2D6 (0.51) | P4HBCYP2D6CYP19A1MEN1KMT2A | |
| SCHEMBL31023713 | 0.76 | CYP2D6 (0.47) | P4HBCYP2D6CYP19A1MEN1KMT2A | |
| SCHEMBL31023723 | 0.75 | SMAD3 (0.42) | P4HBMEN1KMT2AOPRD1SMAD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665718-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2025-12-24 | — | — | EP | disclosed |
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-08-05 | — | — | US | disclosed |
| US-20240294514-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2024-09-05 | — | — | US | disclosed |
| WO-2024168426-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2024-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | MGLL, PNLIP, LPL | P4HB 3538/4885CYP2D6 727/4885CYP19A1 1123/4885 |
| US-20240294514-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | MGLL, PNLIP, LPL | P4HB 3538/4885CYP2D6 727/4885CYP19A1 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.